GlassScriptPhysician profile
Ben Opeyemi Ogunwale
NPI 1720126600
$11,882.21
in general payments reported to CMS, 2019-2025
43 companies · $2,063 in 2025
The $2,063 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,466 · 2020: $1,737 · 2021: $1,777 · 2022: $1,234 · 2023: $1,872 · 2024: $1,733 · 2025: $2,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,555 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,555.09 |
| Education | $112.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,901.69 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,840.61 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,059.15 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Abbvie INC. | $1,044.33 | 2019-2025 | |
| Qol Medical, LLC | $722.28 | 2019-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $611.21 | 2019-2025 | Entyvio, Gattex |
| Ironwood Pharmaceuticals, INC | $546.36 | 2019-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $523.97 | 2023-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $419.53 | 2020-2022 | |
| Ardelyx, INC. | $414.86 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $393.53 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $240.14 | 2020-2021 | |
| Madrigal Pharmaceuticals | $229.96 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $206.31 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $148.30 | 2019-2023 | Ocaliva |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $141.72 | 2025 | Omvoh |
| Redhill Biopharma INC. | $130.70 | 2020-2024 | Talicia |
| Celltrion USA INC. | $117.86 | 2024-2025 | Vegzelma, Zymfentra |
| Ucb, INC. | $116.70 | 2019-2020 | |
| Evoke Pharma, INC. | $102.63 | 2020-2025 | Gimoti |
| Novartis Pharmaceuticals Corporation | $97.76 | 2020 | |
| Davol INC. | $92.38 | 2025 | Phasix Mesh |
| Daiichi Sankyo INC. | $88.38 | 2020-2025 | Injectafer |
| Fresenius Kabi USA, LLC | $88.00 | 2023 | Idacio |
| Novo Nordisk INC | $75.01 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $70.48 | 2021-2024 | Suflave, Sutab |
| Ferring Pharmaceuticals INC. | $66.32 | 2021-2023 | Cimzia, Clenpiq |
| Celgene Corporation | $59.36 | 2023-2024 | Zeposia |
| Amgen INC. | $44.38 | 2020-2021 | |
| Vivus LLC | $36.08 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $32.70 | 2019 | |
| Allergan, INC. | $31.39 | 2020 | |
| Aimmune Therapeutics, INC. | $28.25 | 2025 | Zenpep |
| Fujifilm Healthcare Americas Corporation | $24.01 | 2024 | Utaswako Afp-L3 |
| Merck Sharp & Dohme LLC | $22.81 | 2019-2020 | |
| Shionogi INC | $20.12 | 2019 | |
| Medtronic, INC. | $15.93 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.86 | 2024 | Cyltezo |
| Shire North American Group INC | $15.17 | 2019 | |
| Pfizer INC. | $11.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.69 | 2020 | |
| W. L. Gore & Associates, INC. | $11.47 | 2021 | |
| Thd America, INC. | $10.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben Ogunwale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.